

5741-01-EJF
Application No. 09/284,858

Please replace all prior claims in the application with the following:

Claim 1 (currently amended): A solid pharmaceutical dosage form suitable for oral delivery comprising a solid particulate dispersion of a pharmaceutical agent in a matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical agent in water, the matrix directly contacting the pharmaceutical agent and consisting of a at least one water-soluble polymer, wherein the solid particulate dispersion dosage form is made by mixing the pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften the polymer, but insufficiently high to melt the pharmaceutical agent.

Claim 2 (original): A dosage form of Claim 1 wherein the pharmaceutical agent is a glitazone.

Claims 3-4 (canceled)

Claim 5 (original): A dosage form of Claim 1 wherein the polymer is hydroxypropyl cellulose.

Claims 6-9 (canceled)

Claim 10 (previously presented): The dosage form of Claim 1 wherein said dosage form comprises 75 % by weight of said pharmaceutical agent.

Claims 11-20 (canceled)

Claim 21 (new): A solid pharmaceutical dosage form suitable for oral delivery comprising a solid particulate dispersion of a pharmaceutical agent in a matrix, the pharmaceutical agent being sparingly water-soluble and comprising crystalline particles dispersed in the matrix to enhance the dissolution rate of the pharmaceutical agent in water, the matrix directly contacting the pharmaceutical agent and consisting of at least one water-soluble polymer, wherein the pharmaceutical agent is a glitazone and the solid

After Final Amendment—page 2 of 6

5741-01-EJF
Application No. 09/284,858

particulate dispersion is made by mixing the pharmaceutical agent and the polymer at a temperature sufficiently high to melt or soften the polymer, but insufficiently high to melt the pharmaceutical agent.

Claim 22 (new): A dosage form of Claim 21 wherein the polymer is hydroxypropyl cellulose.

Claim 23 (new): A dosage form of Claim 21 wherein the pharmaceutical agent and the polymer are present at a weight ratio of 75:25, respectively.

After Final Amendment—page 3 of 6